1
|
Liu J, Tang Q, Huang J, Li T, Ouyang H, Lin WH, Yan XJ, Yan X, He S. Sinuscalide A: An Antiviral Norcembranoid with an 8/8-Fused Carbon Scaffold from the South China Sea Soft Coral Sinularia scabra. J Org Chem 2022; 87:9806-9814. [DOI: 10.1021/acs.joc.2c00784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jing Liu
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China
| | - Qi Tang
- Department of Microbiology, The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei 230031, China
| | - Jian Huang
- State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
| | - Te Li
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China
| | - Han Ouyang
- Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang 315211, China
| | - Wen-han Lin
- State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
- Ningbo Institute of Marine Medicine, Peking University, Ningbo, Zhejiang 315800, China
| | - Xiao-jun Yan
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China
| | - Xia Yan
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China
| | - Shan He
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China
- Ningbo Institute of Marine Medicine, Peking University, Ningbo, Zhejiang 315800, China
| |
Collapse
|
2
|
Xu Z, Tang Q, Xu T, Cai Y, Lei P, Chen Y, Zou W, Dong C, Lan K, Wu S, Zhou HB. Discovery of aminothiazole derivatives as novel human enterovirus A71 capsid protein inhibitors. Bioorg Chem 2022; 122:105683. [DOI: 10.1016/j.bioorg.2022.105683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 02/07/2022] [Accepted: 02/09/2022] [Indexed: 12/12/2022]
|
3
|
Tang Q, Xu Z, Zhang F, Cai Y, Chen Y, Lu B, Zhou HB, Lan K, Wu S. Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71. CELL INSIGHT 2022; 1:100016. [PMID: 37193133 PMCID: PMC10120312 DOI: 10.1016/j.cellin.2022.100016] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 01/13/2022] [Accepted: 02/08/2022] [Indexed: 05/18/2023]
Abstract
Enterovirus 71 (EV-A71) infection causes severe hand-foot-and-mouth disease that leads to cardiopulmonary complications and death in young children under 5 years of age. Although there are available vaccines for EV-A71 C4, however, there are no efficient drugs for severe cases. Thus, there is an urgent need to find new direct-antiviral agents (DAAs) to control EV-A71 infection. In this study, we report our discovery of the EV-A71 capsid inhibitor PTC-209HBr, a small-molecule Bmi-1 inhibitor and an anticancer agent, and its derivatives that inhibit multiple enteroviruses with an EC50 at a submicromolar efficacy. The mechanism of action of PTC-209HBr was confirmed by time-of-addition, resistance selection and reverse genetics experiments, microscale thermophoresis (MST), viral binding and entry assays, coimmunoprecipitation (Co-IP) and immunofluorescence experiments (IF). Mechanistic studies indicated that PTC-209HBr inhibited EV-A71 infection by impeding the binding between VP1 and the receptor hSCARB2 during the early stage of EV-A71 infection through hindering viral entry into host cells. Collectively, these findings indicated that PCT-209HBr is a novel inhibitor of enteroviruses with a confirmed mechanism of action that can be further developed into EV-A71 DAAs.
Collapse
Affiliation(s)
- Qi Tang
- Department of Microbiology, The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
| | - Zhichao Xu
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan, 430071, China
| | - Fan Zhang
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
| | - Yang Cai
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
| | - Yinuo Chen
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
| | - Baojing Lu
- Department of Microbiology, The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
| | - Hai-bing Zhou
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan, 430071, China
- Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China
| | - Ke Lan
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
- Medical Research Institute, Wuhan University, Wuhan, 430071, China
| | - Shuwen Wu
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China
| |
Collapse
|
4
|
Liu X, Liang J, Yu Y, Han X, Yu L, Chen F, Xu Z, Chen Q, Jin M, Dong C, Zhou HB, Lan K, Wu S. Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp). J Med Chem 2022; 65:3814-3832. [PMID: 35212527 DOI: 10.1021/acs.jmedchem.1c01257] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Influenza A viruses possess a high antigenic shift, and the approved anti-influenza drugs are extremely limited, which makes the development of novel anti-influenza drugs for the clinical treatment and prevention of influenza outbreaks imperative. Herein, we report a series of novel aryl benzoyl hydrazide analogs as potent anti-influenza agents. Particularly, analogs 10b, 10c, 10g, 11p, and 11q exhibited potent inhibitory activity against the avian H5N1 flu strain with EC50 values ranging from 0.009 to 0.034 μM. Moreover, compound 11q exhibited nanomolar antiviral effects against both the H1N1 virus and Flu B virus and possessed good oral bioavailability and inhibitory activity against influenza A virus in a mouse model. Preliminary mechanistic studies suggested that these compounds exert anti-influenza virus effects mainly by interacting with the PB1 subunit of RNA-dependent RNA polymerase (RdRp). These results revealed that 11q has the potential to become a potent clinical candidate to combat seasonal influenza and influenza pandemics.
Collapse
Affiliation(s)
- Xinjin Liu
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Jinsen Liang
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Yongshi Yu
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Xin Han
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Lei Yu
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Feifei Chen
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Zhichao Xu
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Qi Chen
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Mengyu Jin
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Chune Dong
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China
| | - Hai-Bing Zhou
- Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China.,Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
| | - Ke Lan
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Shuwen Wu
- State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
| |
Collapse
|
5
|
Abdullahi M, Shallangwa GA, Uzairu A. In silico QSAR and molecular docking simulation of some novel aryl sulfonamide derivatives as inhibitors of H5N1 influenza A virus subtype. BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES 2020. [DOI: 10.1186/s43088-019-0023-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
This research provides a comprehensive analysis of QSAR modeling performed on 25 aryl sulfonamide derivatives to predict their effective concentration (EC50) against H5N1 influenza A virus by using some numerical information derived from structural and chemical features (descriptors) of the compounds to generate a statistically significant model. Subsequently, the molecular docking simulations were done so as to determine the binding modes of some potent ligands in the dataset with the M2 proton channel protein of the H5N1 influenza A virus as the target.
Results
In building the QSAR model, the genetic algorithm task was employed in the variable selection of the descriptors which are used to form the multi-linear regression equation. The model with descriptors, RDF100m, nO, and RDF45p, showed satisfactory internal and external validation parameters (R2train = 0.72963, R2adjusted = 0.67169, Q2cv = 0.598, $$ {R}_{\mathrm{pred}}^2= $$Rpred2= 0.67295, R2test = 0.6860) which passed the model criteria of acceptability. Docking simulation results of the more potent compounds (ligands 2, 3, and 8) revealed the formation of hydrophobic and hydrogen bonds with the binding pockets of M2 protein of influenza A virus.
Conclusion
The results in this study can help to advance the research in designing (in silico design) and synthesis of more potent aryl sulfonamides derivatives against H5N1 influenza virus.
Collapse
|
6
|
Chtita S, Aouidate A, Belhassan A, Ousaa A, Taourati AI, Elidrissi B, Ghamali M, Bouachrine M, Lakhlifi T. QSAR study of N-substituted oseltamivir derivatives as potent avian influenza virus H5N1 inhibitors using quantum chemical descriptors and statistical methods. NEW J CHEM 2020. [DOI: 10.1039/c9nj04909f] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In silico modelling studies were executed on thirty two N-substituted oseltamivir derivatives as inhibitors of influenza virus H5N1.
Collapse
Affiliation(s)
- Samir Chtita
- Laboratory Physical Chemistry of Materials
- Faculty of Sciences Ben M’Sik
- Hassan II University of Casablanca
- Casablanca
- Morocco
| | - Adnane Aouidate
- Computer-Aided Drug Discovery Research Center
- Shenzhen Institutes of Advanced Technology
- Chinese Academy of Sciences
- Shenzhen City
- China
| | - Assia Belhassan
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Abdellah Ousaa
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Abdelali Idrissi Taourati
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Bouhya Elidrissi
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Mounir Ghamali
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Mohammed Bouachrine
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| | - Tahar Lakhlifi
- Molecular Chemistry and Natural Substances Laboratory
- Department of chemistry
- Faculty of Sciences
- University Moulay Ismail
- Meknes
| |
Collapse
|
7
|
Chua SCJH, Tan HQ, Engelberg D, Lim LHK. Alternative Experimental Models for Studying Influenza Proteins, Host-Virus Interactions and Anti-Influenza Drugs. Pharmaceuticals (Basel) 2019; 12:E147. [PMID: 31575020 PMCID: PMC6958409 DOI: 10.3390/ph12040147] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 09/11/2019] [Accepted: 09/12/2019] [Indexed: 12/14/2022] Open
Abstract
Ninety years after the discovery of the virus causing the influenza disease, this malady remains one of the biggest public health threats to mankind. Currently available drugs and vaccines only partially reduce deaths and hospitalizations. Some of the reasons for this disturbing situation stem from the sophistication of the viral machinery, but another reason is the lack of a complete understanding of the molecular and physiological basis of viral infections and host-pathogen interactions. Even the functions of the influenza proteins, their mechanisms of action and interaction with host proteins have not been fully revealed. These questions have traditionally been studied in mammalian animal models, mainly ferrets and mice (as well as pigs and non-human primates) and in cell lines. Although obviously relevant as models to humans, these experimental systems are very complex and are not conveniently accessible to various genetic, molecular and biochemical approaches. The fact that influenza remains an unsolved problem, in combination with the limitations of the conventional experimental models, motivated increasing attempts to use the power of other models, such as low eukaryotes, including invertebrate, and primary cell cultures. In this review, we summarized the efforts to study influenza in yeast, Drosophila, zebrafish and primary human tissue cultures and the major contributions these studies have made toward a better understanding of the disease. We feel that these models are still under-utilized and we highlight the unique potential each model has for better comprehending virus-host interactions and viral protein function.
Collapse
Affiliation(s)
- Sonja C J H Chua
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
- NUS Immunology Program, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.
- CREATE-NUS-HUJ Molecular Mechanisms of Inflammatory Diseases Programme, National University of Singapore, Singapore 138602, Singapore.
| | - Hui Qing Tan
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
- NUS Immunology Program, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.
| | - David Engelberg
- CREATE-NUS-HUJ Molecular Mechanisms of Inflammatory Diseases Programme, National University of Singapore, Singapore 138602, Singapore.
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
- Department of Biological Chemistry, The Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.
| | - Lina H K Lim
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
- NUS Immunology Program, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore.
| |
Collapse
|
8
|
Li H, Chen L, Li S, Liao Y, Wang L, Liu Z, Liu S, Song G. Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus. Bioorg Med Chem Lett 2019; 29:2675-2680. [PMID: 31371135 DOI: 10.1016/j.bmcl.2019.07.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 07/09/2019] [Accepted: 07/18/2019] [Indexed: 01/27/2023]
Abstract
The glycoprotein hemagglutinin of influenza virus plays a key role in the initial stage of virus infection, making it a potential target for novel influenza viruses entry inhibitors. Two "privileged fragments", 2-(piperidin-1-yl)ethan-1-amine and 2-(1,3-oxazinan-3-yl)ethan-1-amine were integrated into 3-O-β-chacotriosyl ursolic acid producing new derivatives 5 and 6 with improved activity against IAVs in vitro. Mechanistically, compound 6 was effective in inhibiting infection of H1-, H3-, and H5-typed influenza A viruses by interfering with the viral hemagglutinin. Furthermore, the docking studies were in agreement with the antiviral data. These results showed that the title compound 6 as a new lead compound was meriting further optimization and development.
Collapse
Affiliation(s)
- Hui Li
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
| | - Lizhu Chen
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Sumei Li
- Department of Human Anatomy, School of Medicine, Jinan University, Guangzhou 510632, China
| | - Yixian Liao
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China; State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Integrative Microbiology Research Centre, Guangdong Province Key Laboratory of Microbial Signals and Disease Control, South China Agricultural University, Guangzhou 510642, China
| | - Lei Wang
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
| | - Zhihao Liu
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
| | - Shuwen Liu
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
| | - Gaopeng Song
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China.
| |
Collapse
|
9
|
Liao Y, Chen L, Li S, Cui ZN, Lei Z, Li H, Liu S, Song G. Structure-aided optimization of 3-O-β-chacotriosyl ursolic acid as novel H5N1 entry inhibitors with high selective index. Bioorg Med Chem 2019; 27:4048-4058. [PMID: 31350154 DOI: 10.1016/j.bmc.2019.07.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 07/12/2019] [Accepted: 07/17/2019] [Indexed: 01/11/2023]
Abstract
Currently, entry inhibitors contribute immensely in developing a new generation of anti-influenza virus drugs. Our earlier studies have identified that 3-O-β-chacotriosyl ursolic acid (1) could inhibit H5N1 pseudovirus by targeting hemagglutinin (HA). In the present study, a series of C-28 modified pentacyclic triterpene saponins via conjugation with a series of amide derivatives were synthesized and their antiviral activities against influenza A/Duck/Guangdong/99 virus (H5N1) in MDCK cells were evaluated. The SARs analysis of these compounds revealed that introduction of certain amide structures at the 17-COOH of ursolic acid could significantly enhance both their antiviral activity and selective index. This study indicated that the attachment of the methoxy group or Cl atom to the phenyl ring at the ortho- or para-position was crucial to improve inhibitory activity. Mechanism studies demonstrated that these title triterpenoids could bind tightly to the viral envelope HA to block the attachment of viruses to host cells, which was consistent with docking studies.
Collapse
Affiliation(s)
- Yixian Liao
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China; State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Integrative Microbiology Research Centre, Guangdong Province Key Laboratory of Microbial Signals and Disease Control, South China Agricultural University, Guangzhou 510642, China
| | - Lizhu Chen
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Sumei Li
- Department of Human Anatomy, School of Medicine, Jinan University, Guangzhou 510632, China
| | - Zi-Ning Cui
- State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Integrative Microbiology Research Centre, Guangdong Province Key Laboratory of Microbial Signals and Disease Control, South China Agricultural University, Guangzhou 510642, China
| | - Zhiwei Lei
- Guizhou Tea Reasearch Institute, Guizhou Academy of Agricultural Science, Guiyang, Guizhou 550006, China
| | - Hui Li
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
| | - Shuwen Liu
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
| | - Gaopeng Song
- College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China.
| |
Collapse
|
10
|
Wang Z, Hu X, Li Y, Mou X, Wang C, Chen X, Tan Y, Wu C, Liu H, Xu H. Discovery and SAR Research for Antivirus Activity of Novel Butenolide on Influenza A Virus H1N1 In Vitro and In Vivo. ACS OMEGA 2019; 4:13265-13269. [PMID: 31460454 PMCID: PMC6705239 DOI: 10.1021/acsomega.9b01421] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Accepted: 07/22/2019] [Indexed: 05/30/2023]
Abstract
Influenza viruses (IV) cause substantial morbidity and mortality through routine seasonal spread and epidemics. A novel series of butenolides were discovered to be able to inhibit influenza H1N1 activity in vitro, and the SAR for anti-influenza activity was investigated. By optimization of the hit compound, compound 37 was obtained with an EC50 of 6.7 μM against influenza A virus H1N1 as an inhibitor of NA and with low cytotoxicity on MDCK cells. Also, it can inhibit the expression of the influenza A virus gene in the lung of SPF KM mice to show antivirus activity in vivo. These results suggested that compound 37 could inhibit the influenza A virus H1N1 via targeting NA.
Collapse
Affiliation(s)
- Zhenya Wang
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Xiaoning Hu
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Yuanyuan Li
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Xiaodong Mou
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Congcong Wang
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Xinli Chen
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Yayun Tan
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Chunli Wu
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Hongmin Liu
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| | - Haiwei Xu
- Collaborative
Innovation Center of New Drug Research and Safety Evaluation,
Henan Province; Key Laboratory of Advanced Drug Preparation Technologies,
Ministry of Education and Key Laboratory of “Runliang” Antiviral
Medicines Research and Development, Institute of Drug Discovery &
Development, Zhengzhou University, No. 100, KeXueDaDao, Zhengzhou 450001, China
| |
Collapse
|